GW Pharmaceuticals

History of GW Pharmaceuticals

• Founded in 1998 by doctors Geoffrey Guy and Brian Whittle.
• Obtained cultivation license from the UK Home Office and MHRA in 1998.
• Entered a contract with Hortapharm B.V. in 1998.
• Listed on the Alternative Investment Market in 2001.
• Dual-listed on NASDAQ and AIM in May 2013.

Products Developed by GW Pharmaceuticals

• Sativex (Nabiximols) approved in the UK in 2010 for MS patients.
• Partnership with Bayer for Sativex distribution in the UK in 2020.
• Estimated annual production of 100 tons of medicinal cannabis.
• Epidiolex (cannabidiol oral solution) approved by FDA in June 2018.

Sativex by GW Pharmaceuticals

• Administered as a mouth spray.
• Approved in the UK for multiple sclerosis patients.
• Extracted with ethanol and carbon dioxide.
• Annual production estimated at 100 tons.
• Partnership with Bayer for UK distribution.

Epidiolex by GW Pharmaceuticals

• Phase 3 clinical trials initiated in 2015 for Dravet syndrome and Lennox–Gastaut syndrome.
• Received FDA Fast Track Development Program designation in 2015.
• FDA approved Epidiolex in June 2018.
• European EMA approval under the brand name Epidyolex in September 2019.
• Used for newborns with epilepsy.

Related Concepts and Products

• Cannabis portal.
• Dronabinol.
• Marinol.
• Nabilone.
• Medical use of cannabis.

GW Pharmaceuticals Data Sources